TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE

Detalles Bibliográficos
Main Authors:	Elsone, L, Leite, M, Brown, R, McNeillis, B, Palace, J, Boggild, Jacob, M
Formato:	Conference item
Publicado:	2012

Títulos similares

Is azathioprine effective in highly-active neuromyelitis optica? A multicentre study from the United Kingdom
por: Elsone, L, et al.
Publicado: (2013)

Long term efficacy, adherence and reasons for discontinuation in 103 cases of neuromyelitis optica treated with azathioprine: a multicentre study from the United Kingdom
por: Elsone, L, et al.
Publicado: (2013)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
por: Kitley, J, et al.
Publicado: (2012)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
por: Kitley, J, et al.
Publicado: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
por: Kitley, J, et al.
Publicado: (2013)

Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
por: Elsone, L, et al.
Publicado: (2014)

DIFFERENCES IN OUTCOMES IN NEUROMYELITIS OPTICA BETWEEN A JAPANESE COHORT AND A PREDOMINANTLY CAUCASIAN COHORT FROM THE UK
por: Kitley, J, et al.
Publicado: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
por: Kitley, J, et al.
Publicado: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
por: Kitley, J, et al.
Publicado: (2012)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
por: Kitley, J, et al.
Publicado: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
por: Kitley, J, et al.
Publicado: (2014)

Neuromyelitis optica
por: Jacob Anu, et al.
Publicado: (2007-01-01)

A practical guide to the treatment of neuromyelitis optica.
por: Palace, J, et al.
Publicado: (2012)

Seasonal pattern of variation in neuromyelitis optica relapses
por: Elsone, L, et al.
Publicado: (2012)

Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
por: Ana Beatriz Ayroza Galvão Ribeiro GOMES, et al.
Publicado: (2021-03-01)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
por: Littleton, E, et al.
Publicado: (2006)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
por: Collongues, N, et al.
Publicado: (2013)

Use of mitoxantrone in neuromyelitis optica.
por: Kitley, J, et al.
Publicado: (2011)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
por: Kitley, J, et al.
Publicado: (2013)

The borderland of neuromyelitis optica.
por: Matthews, L, et al.
Publicado: (2009)

Treatment of Neuromyelitis Optica: Review and Recommendations.
por: Kimbrough, D, et al.
Publicado: (2012)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Waters, P, et al.
Publicado: (2015)

Treatment of neuromyelitis optica: Review and recommendations
por: Kimbrough, D, et al.
Publicado: (2012)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
por: Luppe, S, et al.
Publicado: (2012)

Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders
por: Xindi Li, et al.
Publicado: (2017-07-01)

Magnetic resonance imaging in neuromyelitis optica.
por: Tackley, G, et al.
Publicado: (2014)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
por: Palace, J, et al.
Publicado: (2010)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
por: Matthews, L, et al.
Publicado: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
por: Matthews, L, et al.
Publicado: (2013)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
por: Downer, J, et al.
Publicado: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
por: Downer, J, et al.
Publicado: (2012)

The evolving clinical spectrum of neuromyelitis optica
por: Viegas, S, et al.
Publicado: (2008)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
por: Viegas, S, et al.
Publicado: (2009)

Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
por: Waters, P, et al.
Publicado: (2008)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
por: Fujihara, K, et al.
Publicado: (2014)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
por: Kim, W, et al.
Publicado: (2012)

A mathematical model of cellular swelling in Neuromyelitis optica
por: Laranjeira, S, et al.
Publicado: (2017)

LONG TERM OUTCOME IN NEUROMYELITIS OPTICA: LESSONS FROM 6 YEARS OF THE UK NMO STUDY
por: Jacob, A, et al.
Publicado: (2009)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
por: Absoud, M, et al.
Publicado: (2014)

NMO-IgG in the diagnosis of neuromyelitis optica.
por: Jarius, S, et al.
Publicado: (2007)